Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

March 13, 2024 updated by: The Lymphoma Academic Research Organisation
Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells. Bispecific antibodies (BsAb) are a promising treatment option which can induce long-term responses in refractory and relapsed B cell lymphoma patients. However, the factors determining the quality and duration of responses are poorly understood.

Study Overview

Status

Recruiting

Conditions

Detailed Description

the objective is to produce a collection of great scientific interest for lymphoma research from CELESTIMO's clinical trial patients' samples to increase knowledge of treatment with mosunetuzumab's for patients with follicular lymphoma (FL).

study population involves patients participating to CELESTIMO study in France. 10 sites are expected in this biobanking protocol study

Biological samples will collected as part of routine care (tissue and blood already sampled in routine and/or CELESTIMO study) at screening, at C4, at C12 or at progressive disease/relapse.

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Bayonne, France, 64109
        • Recruiting
        • Centre Hospitalier de La Cote Basque; Hematologie
        • Contact:
        • Principal Investigator:
          • Jean-Baptiste Robin, MD
      • Lille, France, 59037
        • Recruiting
        • Hopital Claude Huriez; Hematologie
        • Principal Investigator:
          • FRANCK MORSCHHAUSER, MD
        • Contact:
      • Marseille, France, 13273
        • Recruiting
        • Institut Paoli Calmettes
        • Contact:
        • Principal Investigator:
          • Jean Marc Schiano de Colella, MD
      • Montpellier, France, 34295
        • Recruiting
        • CHU Saint Eloi; Service d'Hématologie Clinique
        • Principal Investigator:
          • Guillaume Cartron, MD
        • Contact:
      • Nantes cedex 1, France, 44000
        • Recruiting
        • CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique
        • Principal Investigator:
          • Benoit Tessoulin, MD
        • Contact:
      • Nîmes, France, 30029
        • Recruiting
        • CHU de Nîmes - Hôpital Caremeau
        • Principal Investigator:
          • Agathe Waultier-Rascalou, MD
        • Contact:
      • Paris, France, 75012
        • Recruiting
        • Hopital Saint Antoine; Hematologie Clinique
        • Contact:
        • Principal Investigator:
          • Remy DULERY, MD
      • Poitiers, France, 86021
        • Recruiting
        • Hopital De La Miletrie; Hematologie Et Oncologie Medicale
        • Contact:
        • Principal Investigator:
          • Stéphanie Guidez, MD
      • Rennes, France, 35033
        • Recruiting
        • CHU Pontchaillou
        • Contact:
        • Principal Investigator:
          • Roch Houot, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients who participate to CELESTIMO study (NCT04712097)

Description

patients who participate to CELESTIMO study (NCT04712097)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Capacity of sampling
Time Frame: 2 years
number of samples collected
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

Roche Pharma AG

Investigators

  • Principal Investigator: Camille Laurent, MD, Oncopole - Toulouse France
  • Principal Investigator: Karin Tarte, PhD, Micro-environnement et cancer (MICA) - Rennes France
  • Principal Investigator: Franck MORSCHHAUSER, MD, Centre Hospitalier Universitaire de Lille - Lille France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 7, 2022

Primary Completion (Estimated)

September 1, 2024

Study Completion (Estimated)

September 1, 2024

Study Registration Dates

First Submitted

September 2, 2022

First Submitted That Met QC Criteria

September 2, 2022

First Posted (Actual)

September 7, 2022

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 13, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CALC

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Follicular Lymphoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe